Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
OSE selected by Microsoft France to join the “Biotech Scaler Program” launched during “Viva Technology”, the European Startup and Tech event.This collaboration will give OSE the opportunity to further...
-
The Scientific Advisory Board (SAB) combines the expertise of renowned scientific and international key-opinion leaders in the fields of immunology, immuno-oncology, inflammation and immunotherapy.The...
-
NSCLC Atalante-1 Phase 3 Trial Beyond Checkpoint Inhibitor Neoepitope Specific Immunotherapy Tedopi® Shows Significant Patient-Reported Outcomes Versus ChemotherapyPositive Interim Results in Phase 2...
-
NANTES, France, May 23, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione...
-
A Phase 1 Study Sponsored and Conducted by Veloxis Pharmaceuticals, Inc., the Company’s Partner in Transplantation NANTES, France, May 18, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:...
-
NANTES, France, May 11, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) has been invited to provide an update on its R&D programs in immuno-oncology at two...
-
Initiation of the Phase 1 clinical expansion trial triggers a €10 million milestone payment from Boehringer Ingelheim to OSE Immunotherapeutics.The trial is being conducted in advanced hepatocellular...
-
A new protection covering CLEC-1 antagonists until 2037Patent also granted in Japan and notice of allowance granted in the US NANTES, France, May 02, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics...
-
At American Association for Cancer Research Annual (AACR) Meeting 2022New Orleans, April 8 – 13 NANTES, France, April 04, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173;...
-
Shared positive final Phase 3 results for Tedopi® in non-small cell lung cancer (NSCLC) patients in secondary resistance after failure with second-line checkpoint inhibitor treatment.Received an €8...